Switching from Semaglutide to Tirzepatide: Ozempic/Wegovy to Zepbound/Mounjaro

Written by the GLP-1 Coach editorial team. Last updated August 28, 2026.

If you're on semaglutide (Ozempic or Wegovy) and wondering whether tirzepatide (Zepbound or Mounjaro) would work better for you, you're not alone — it's one of the most common medication questions in GLP-1 communities right now, and there's now a real head-to-head trial to look at instead of just cross-trial comparisons. Here's what the switch actually involves: why people make it, how re-titration works, what the first few weeks tend to feel like, and how to set it up correctly in GLP-1 Coach.

Why people switch

The most direct evidence comes from SURMOUNT-5, a phase 3b trial that randomized 751 adults with obesity (without type 2 diabetes) to either maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks — a genuine head-to-head comparison rather than two separate trials being compared after the fact.

Result at week 72:

	Tirzepatide	Semaglutide
Mean weight change	−20.2%	−13.7%
Waist circumference change	−18.4 cm	−13.0 cm
Discontinued due to GI adverse events	2.7%	5.6%

The weight-loss difference was statistically significant (p<0.001). Tirzepatide also produced a larger reduction in waist circumference, and — notably — a lower rate of stopping treatment because of GI side effects, which cuts against the assumption that more effective automatically means less tolerable.

The leading explanation for the efficacy gap is mechanistic: semaglutide activates the GLP-1 receptor only, while tirzepatide activates both GLP-1 and GIP receptors. SURMOUNT-5 measured the outcome of that difference; it wasn't designed to isolate the receptor mechanism itself, so that explanation is the field's best current account, not something this specific trial proved in isolation.

Worth noting on trial design: participants were dosed at maximum tolerated doses on both drugs (not matched mg-for-mg, which isn't possible between two different molecules), and the comparison excluded people with type 2 diabetes. If your reason for taking a GLP-1 is diabetes management rather than weight management, talk to your prescriber about how that changes the picture — SURMOUNT-5 doesn't directly speak to that population.

How re-titration works when you switch

This is the part most people get wrong by assumption: switching to tirzepatide does not mean starting at a "matching" dose based on where you left off on semaglutide.

Zepbound and Mounjaro prescribing information sets the starting dose at 2.5 mg weekly "for all indications" — there's no carve-out in the label for patients arriving from another GLP-1 medication, and no FDA-recognized dose-equivalence table between semaglutide and tirzepatide. Practically, this means:

• You restart at 2.5 mg tirzepatide, regardless of whether you were on 0.25 mg or 2.4 mg semaglutide. Being at the top of the semaglutide dose range doesn't let you skip ahead on tirzepatide — the two drugs aren't calibrated against each other.
• You follow the standard titration schedule from there: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, with a minimum of 4 weeks on each dose before stepping up, per the same schedule every new tirzepatide patient uses.
• The label does not recommend taking both drugs at once. Zepbound and Mounjaro prescribing information states that coadministration with any GLP-1 receptor agonist is not recommended. Because semaglutide has a roughly 7-day half-life and takes about 5 weeks to fully clear, and tirzepatide has a shorter ~5-day half-life, the practical question of exactly how much gap to leave between your last semaglutide dose and your first tirzepatide dose is a prescriber decision — this article isn't the source for that specific timing, your prescriber is.

Re-titration to a therapeutic tirzepatide dose (typically 10–15 mg, based on where SURMOUNT-5 dosed its tirzepatide arm) follows the same step-up schedule as starting tirzepatide for the first time — your prescriber will set the pacing based on how you tolerate each step, not a fixed calendar.

Why the "restart at the bottom" rule exists: semaglutide and tirzepatide are different molecules with different receptor targets — there's no validated conversion between "0.5 mg semaglutide" and "some mg of tirzepatide." Starting low and re-titrating is the same GI-tolerance-building process every new GLP-1 patient goes through, applied again because pharmacologically, tirzepatide is a new medication to your system, not a stronger dose of your old one.

What to expect in the first few weeks

Because you're restarting titration, the first few weeks of tirzepatide tend to resemble your original semaglutide start more than a continuation of where you left off:

• GI side effects often reset. Nausea, early fullness, or mild GI symptoms commonly reappear around the first dose and again at each step-up — the same pattern documented for GLP-1 titration generally, not something specific to switching.
• Appetite suppression at 2.5 mg is intentionally mild. The starting dose exists to build tolerance, not to produce the appetite effect you were used to at your semaglutide maintenance dose. Expect appetite control to feel closer to "somewhat reduced" than "the way it felt at your top semaglutide dose" until you reach a therapeutic tirzepatide dose.
• A short window where hunger feels less controlled is common. If your prior semaglutide dose was providing strong appetite suppression, the gap between stopping it and reaching a comparable tirzepatide dose can feel like a step backward for a few weeks. This is expected pharmacology, not a sign the switch isn't working.
• Tolerability may — on average — be somewhat easier, per SURMOUNT-5's lower GI-discontinuation rate for tirzepatide (2.7%) vs. semaglutide (5.6%). That's a trial-level average across hundreds of participants, not a guarantee for any individual — some people tolerate semaglutide better, and switching doesn't reset that individual variation.

The same fundamentals that protected muscle and managed side effects on semaglutide still apply here: protein target, structured meals during nausea windows, and treating the re-titration period as its own adjustment phase rather than expecting immediate continuity.

Setting up the switch in GLP-1 Coach

The app's medication and dosing logic already treats semaglutide and tirzepatide as distinct molecules — half-life, dose-warning thresholds, and titration steps are all tracked separately per medication, so switching doesn't require any workaround:

1. Go to Settings → Medication and update your medication to Mounjaro · Zepbound (tirzepatide). Your logged history isn't deleted — past entries stay attached to your prior medication.
2. Your week count restarts from today for the new medication, which matters for how the app frames your titration stage and nausea-pattern insights — it won't compare your first tirzepatide week to your twelfth semaglutide week.
3. Update your pen/dose selection to the 2.5 mg Mounjaro · Zepbound starting dose (or whatever your prescriber has actually started you on) so dose logging and the medication-level chart reflect the real molecule and dose, not a leftover semaglutide value.
4. The taper/PK curve and dose-insight tooling recalculate cleanly once your medication is updated — the underlying half-life and dose-ceiling values are keyed to tirzepatide specifically, so nausea-pattern tracking and the medication-level curve won't carry over semaglutide's decay curve into your new tirzepatide entries.

If you're also using the taper planner, start a new projection after the switch — a projection built on your old semaglutide data won't reflect tirzepatide's shorter half-life or your new dose schedule.

The bottom line

Bottom line: SURMOUNT-5 found tirzepatide produced meaningfully greater weight loss than semaglutide head-to-head (20.2% vs. 13.7% at 72 weeks, p<0.001), with fewer people stopping due to GI side effects. But switching isn't a dose upgrade — Zepbound and Mounjaro's label starts everyone at 2.5 mg regardless of prior semaglutide dose, with no recommended overlap between the two drugs. Expect a re-titration period that feels more like starting over than leveling up — the same step-up schedule and prescriber-set pacing as any new tirzepatide start — before judging how the switch is working for you.

---

Related:

• Ozempic vs Wegovy vs Mounjaro: Side Effects Compared Week by Week
• Stopping Mounjaro or Zepbound: What to Expect
• Ozempic Titration: What Changes at Each Dose

---

This article is educational and not a substitute for medical advice. The decision to switch medications, the starting dose, and the timing between your last semaglutide dose and your first tirzepatide dose should be made with the prescriber managing your care — not inferred from this article.

Sources: Aronne LJ, Horn DB, le Roux CW, et al., "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity," SURMOUNT-5, New England Journal of Medicine 2025;393:26-36; SURMOUNT-5 trial registration, ClinicalTrials.gov NCT05822830; Zepbound prescribing information, Eli Lilly; Mounjaro prescribing information, Eli Lilly; ZEPBOUND full prescribing information, DailyMed/FDA; Ozempic prescribing information, Novo Nordisk; Wegovy dosing schedule, Novo Nordisk.